Preliminary evidence showed that activation of alternative RTKs may contribute largely to therapeutic resistance and accumulating reports determined an increase of AKT activity in sunitinib-refractory ccRCC [31]. This evidence concerns the gene AKT1 and nonpapillary renal cell carcinoma.